Abstract
One of the most common crucial cancer that occur in femal is the ovarian cancer. Approximately evaluated new cases 21,550 and deaths 14,600 from ovarian cancer in the America in 2009. "Human Epidermal growth factor Receptor 1" HER2 it's once of agents stands and is a protein show higher rate of offensive in ovarian cancer. HER2 most famous protein which target in Herceptin therapy of ovarian cancer in metastatic status in case the tumor resulting of protein over expression. FISH technique used on TMA with HER2 specific probes it is the most commonly prove method had been use and have important role in analysis for HER2 status revelation and copy number changes. In this study we detected HER2 overexpression and cytogenetic analysis in ovarian cancer patients by using new technology tissue microarrays (TMA) and Fluorescence In Situ Hybridization (FISH). In tumors with low malignant potential there is no amplification also that we are found in Benign ovarian tumors. While we notice that HER2 increase in malignancies tumor, low malignant ovarian tumors and finally in benign ovarian tumors. In conclusion conceder the detecting and simultaneous quantification of HER2 overexpression gene by means of FISH assay, might enable the showing of a more precise stratification of ovarian cancer patients.
Highlights
Ovarian cancer is one of the most widespread fatal full cancer of the female
We investigated HER2 in 303 women with ovarian cancer 192 were malignancies tumors (179 epithelial and 13 non epithelial ),18 low malignant ovarian tumors( just epithelial ), 93 – Benign ovarian tumors(77 epithelial and 16 non epithelial The method of Fluorescence In Situ Hybridization (FISH) applied on adequately prepared ovarian tumor tissue microchips was used for HER2 gene examination by specific probes proved itself as the most commonly used and valuable analysis for routine HER2 status detection(Hauptmann et al, 2002)
FISH method used on tissue microarrays (TMA) with specific probe for the examined HER2 oncogene, has realized amplification and genetic gain frequency detection, enabling evaluation of the input of this oncogene rearrangements for the ovarian tumor occurrence and progression
Summary
Ovarian cancer is one of the most widespread fatal full cancer of the female. Recently, it is in the fourth level of the cancer that most common and lead to cancer death in the United Kingdom female, while the breast, lung, and colorectal cancer is occupied the first three level (Jemal et al, 2007). According to WHO, types of ovarian cancers in women age 20 are as follows: 1-Surface epithelial-stromal tumour, known as ovarian epithelial carcinoma, is the most common type of ovarian cancer. It includes serous tumour, endometriosis tumour and mucinous cystadenocarcinoma. Several new agents targeting specific and critical pathways for ovarian cancer (Olayioye , 2001) One of these agents HER2/neu ( known as ErbB-2, ERBB2) stands for "Human Epidermal growth factor Receptor 2" and is a protein giving higher aggressiveness in ovarian cancer(Santin et al,2008).HER2-neu is member of the erbB gene
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
